Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77


An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein.

McCready J, Wong DS, Burlison JA, Ying W, Jay DG.

Cancers (Basel). 2014 Apr 30;6(2):1031-46. doi: 10.3390/cancers6021031.


Detection and Analysis of Extracellular Hsp90 (eHsp90).

Cortes S, Baker-Williams AJ, Mollapour M, Bourboulia D.

Methods Mol Biol. 2018;1709:321-329. doi: 10.1007/978-1-4939-7477-1_23.


Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally.

Li W, Tsen F, Sahu D, Bhatia A, Chen M, Multhoff G, Woodley DT.

Int Rev Cell Mol Biol. 2013;303:203-35. doi: 10.1016/B978-0-12-407697-6.00005-2. Review.


Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.

Hance MW, Dole K, Gopal U, Bohonowych JE, Jezierska-Drutel A, Neumann CA, Liu H, Garraway IP, Isaacs JS.

J Biol Chem. 2012 Nov 2;287(45):37732-44. doi: 10.1074/jbc.M112.389015. Epub 2012 Sep 18.


Emerging Roles of Extracellular Hsp90 in Cancer.

Wong DS, Jay DG.

Adv Cancer Res. 2016;129:141-63. doi: 10.1016/bs.acr.2016.01.001. Epub 2016 Jan 21. Review.


The double-edged sword: conserved functions of extracellular hsp90 in wound healing and cancer.

Hance MW, Nolan KD, Isaacs JS.

Cancers (Basel). 2014 May 6;6(2):1065-97. doi: 10.3390/cancers6021065.


Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity.

Nolan KD, Kaur J, Isaacs JS.

Oncotarget. 2017 Mar 21;8(12):19323-19341. doi: 10.18632/oncotarget.14252.


A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion.

Gopal U, Bohonowych JE, Lema-Tome C, Liu A, Garrett-Mayer E, Wang B, Isaacs JS.

PLoS One. 2011 Mar 8;6(3):e17649. doi: 10.1371/journal.pone.0017649.


Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.

Nolan KD, Franco OE, Hance MW, Hayward SW, Isaacs JS.

J Biol Chem. 2015 Mar 27;290(13):8271-82. doi: 10.1074/jbc.M115.637496. Epub 2015 Feb 10.


Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling.

Daoud A, Gopal U, Kaur J, Isaacs JS.

Oncotarget. 2017 Nov 3;8(63):106807-106819. doi: 10.18632/oncotarget.22370. eCollection 2017 Dec 5.


Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer.

Kasashima H, Yashiro M, Kinoshita H, Fukuoka T, Morisaki T, Masuda G, Sakurai K, Kubo N, Ohira M, Hirakawa K.

Cancer Lett. 2014 Nov 28;354(2):438-46. doi: 10.1016/j.canlet.2014.08.014. Epub 2014 Aug 13.


Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.

Chang J, Lucas MC, Leonte LE, Garcia-Montolio M, Singh LB, Findlay AD, Deodhar M, Foot JS, Jarolimek W, Timpson P, Erler JT, Cox TR.

Oncotarget. 2017 Apr 18;8(16):26066-26078. doi: 10.18632/oncotarget.15257.


A molecular role for lysyl oxidase in breast cancer invasion.

Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, Hendrix MJ.

Cancer Res. 2002 Aug 1;62(15):4478-83.


Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1.

Kim BR, Dong SM, Seo SH, Lee JH, Lee JM, Lee SH, Rho SB.

Cell Signal. 2014 Sep;26(9):1765-73. doi: 10.1016/j.cellsig.2014.05.010. Epub 2014 May 24.


UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

Landmann H, Proia DA, He S, Ogawa LS, Kramer F, Bei├čbarth T, Grade M, Gaedcke J, Ghadimi M, Moll U, Dobbelstein M.

Cell Death Dis. 2014 Sep 11;5:e1411. doi: 10.1038/cddis.2014.378.


Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is critically required for differentiation.

Iftikhar M, Hurtado P, Bais MV, Wigner N, Stephens DN, Gerstenfeld LC, Trackman PC.

J Biol Chem. 2011 Jan 14;286(2):909-18. doi: 10.1074/jbc.M110.155622. Epub 2010 Nov 11.


A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo.

Crowe LB, Hughes PF, Alcorta DA, Osada T, Smith AP, Totzke J, Loiselle DR, Lutz ID, Gargesha M, Roy D, Roques J, Darr D, Lyerly HK, Spector NL, Haystead TAJ.

ACS Chem Biol. 2017 Apr 21;12(4):1047-1055. doi: 10.1021/acschembio.7b00006. Epub 2017 Feb 23.


MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.

Moon HJ, Finney J, Xu L, Moore D, Welch DR, Mure M.

J Biol Chem. 2013 Oct 18;288(42):30000-8. doi: 10.1074/jbc.C113.502310. Epub 2013 Sep 6.


Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor.

Rodriguez HM, Vaysberg M, Mikels A, McCauley S, Velayo AC, Garcia C, Smith V.

J Biol Chem. 2010 Jul 2;285(27):20964-74. doi: 10.1074/jbc.M109.094136. Epub 2010 May 3.


Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K.

Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.

Supplemental Content

Support Center